U.S. pharmaceutical company Pfizer announced on Friday that its innovative migraine** has been approved in China for the acuteness of migraine, with or without warning signs.
Pfizer claims that this ** is the world's first and only oral drug for this purpose that can block key pathways associated with migraine pathogenesis.
The company claims that it provides quick and sustained relief from headaches and related symptoms.
Currently, this method is the only one in the world that has been approved in both the United States and the European Union, and has been recommended by migraine guidelines in the United States, Europe, and China.
Pfizer expects the approval to provide a new and valuable option for migraine sufferers in China.
Jean-Christophe Pointeau, senior vice president of Pfizer and president of Pfizer China, said: "Neuroscience is the focus of Pfizer's in-depth research and expansion. The approval of the new drug in China is expected to help Chinese migraine patients improve their quality of life. This is also an important embodiment of the company's commitment to establishing a foothold in the Chinese market and serving Chinese patients. ”
Migraine is a common debilitating condition that is often accompanied by complications such as anxiety, depression, cerebrovascular disease, and sleep disorders, resulting in a heavy disease burden. Experts estimate that the prevalence of the disease in China is about 9%.